Ultrasound Demonstrates Continued Improvement in Psoriatic Arthritis Synovitis and Enthesitis with Secukinumab: 52-week Results from a Phase III Study

被引：0

作者：

D'Agostino, Maria Antonietta ^{[1
]}

Schett, Georg ^{[2
]}

Gaillez, Corine ^{[3
]}

Guerrero, Carlos ^{[4
]}

Hanova, Petra ^{[5
]}

Cazenave, Tomas ^{[6
]}

Stoenoiu, Maria S. ^{[7
]}

Backhaus, Marina ^{[8
]}

Mouterde, Gael ^{[9
]}

Boers, Maarten ^{[10
,11
]}

Duggan, Anne-Marie ^{[12
]}

Goyanka, Punit ^{[13
]}

Conaghan, Philip ^{[14
]}

机构：

[1] Fdn Policlin Univ Gemelli, IRCCS, Rheumatol, Rome, Italy

[2] Univ Klinikum Erlangen, Dept Internal Med Rheumatol & Immunol 3, Erlangen, Germany

[3] Novartis Pharma AG, Basel, Switzerland

[4] Dermatol Country, Guadalajara, Jalisco, Mexico

[5] Inst Rheumatol, Dept Rheumatol, Prague, Czech Republic

[6] Inst Rehabil Psicofis, Buenos Aires, DF, Argentina

[7] Clin Univ St Luc, Inst Rech Expt & Clin IREC, Rheumatol Dept, Brussels, Belgium

[8] Pk Klin Weissensee Acad Hosp Charite, Dept Internal Med Rheumatol & Clin Immunol, Berlin, Germany

[9] CHU Montpellier, Rheumatol Dept, Montpellier, France

[10] Vrije Univ, Dept Epidemiol & Data Sci, Amsterdam, Netherlands

[11] Vrije Univ, Amsterdam UMC, Amsterdam Rheumatol & Immunol Ctr, Amsterdam, Netherlands

[12] Novartis Ireland Ltd, Dublin, Ireland

[13] Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, India

[14] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England

来源：

ARTHRITIS & RHEUMATOLOGY | 2021年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1360

引用

页码：2839 / 2842

页数：4

共 50 条

[1] ULTRASOUND DEMONSTRATES CONTINUED IMPROVEMENT IN PSORIATIC ARTHRITIS SYNOVITIS AND ENTHESITIS WITH SECUKINUMAB: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Conaghan, Philip G.
D'Agostino, Maria A.
Schett, Georg
Guerrero, Carlos
Hanova, Petra
Cazenave, Tomas
Stoenoiu, Maria S.
Backhaus, Marina
Mouterde, Gael
Boers, Maarten
Duggan, Anne-Marie
Goyanka, Punit
Gaillez, Corine
RHEUMATOLOGY, 2022, 61 : I139 - I139
[2] Effects of secukinumab on synovitis and enthesitis in patients with psoriatic arthritis: 52-week clinical and ultrasound results from the randomised, double-blind ULTIMATE trial with open label extension
D'Agostino, Maria Antonietta
Carron, Philippe
Gaillez, Corine
Conaghan, Philip G.
Naredo, Esperanza
Lopez-Rdz, Alejandra
Senolt, Ladislav
Burgos-Vargas, Ruben
Hanova, Petra
Padovano, Ilaria
Cazenave, Tomas
Stoenoiu, Maria S.
Backhaus, Marina
Mouterde, Gael
Bao, Weibin
Goyanka, Punit
Boers, Maarten
Schett, Georg
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2023, 63
[3] Secukinumab Provides Improvement in Nail Psoriasis and Inhibition of Radiographic Progression in Psoriatic Arthritis Patients with Nail Phenotype: 52-Week Results from a Phase III Study
Nash, Peter
Mease, Philip
Kirkham, Bruce
Balsa, Alejandro
Singhal, Atul
Quebe-Fehling, Erhard
Pricop, Luminita
Gaillez, Corine
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[4] Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE
D'Agostino, Maria Antonietta
Schett, Georg
Lopez-Rdz, Alejandra
Senolt, Ladislav
Fazekas, Katalin
Burgos-Vargas, Ruben
Maldonado-Cocco, Jose
Naredo, Esperanza
Carron, Philippe
Duggan, Anne-Marie
Goyanka, Punit
Boers, Maarten
Gaillez, Corine
RHEUMATOLOGY, 2022, 61 (05) : 1867 - 1876
[5] SECUKINUMAB PROVIDES SIGNIFICANT AND SUSTAINED IMPROVEMENT IN NAIL PSORIASIS AND SIGNS AND SYMPTOMS OF PSORIATIC ARTHRITIS IN PATIENTS WITH NAIL PHENOTYPE: 52-WEEK RESULTS FROM THE PHASE III FUTURE 5 STUDY
Nash, Peter
Mease, Philip J.
Kirkham, Bruce
Balsa, Alejandro
Singhal, Atul
Quebe-Fehling, Erhard
Pricop, Luminita
Gaillez, Corine
ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 921 - +
[6] COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY
Gottlieb, Alice
Behrens, Frank
Nash, Peter
Merola, Joseph F.
Pellet, Pascale
Pricop, Luminita
McInnes, Iain
RHEUMATOLOGY, 2021, 60
[7] COMPARISON OF SECUKINUMAB VERSUS ADALIMUMAB EFFICACY ON SKIN OUTCOMES IN PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM THE EXCEED STUDY
Gottlieb, A. B.
Behrens, F.
Nash, P.
Merola, J. F.
Ding, K.
Pellet, P.
Pricop, L.
Mcinnes, I.
ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 759 - 760
[8] Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5
van der Heijde, Desiree
Mease, Philip J.
Landewe, Robert B. M.
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Boettcher, Elke
Navarra, Sandra
Zhu, Xuan
Ligozio, Gregory
Readie, Aimee
Mpofu, Shephard
Pricop, Luminita
RHEUMATOLOGY, 2020, 59 (06) : 1325 - 1333
[9] SUBCUTANEOUS SECUKINUMAB PROVIDES SUSTAINED INHIBITION OF RADIOGRAPHIC PROGRESSION IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK RESULTS FROM A PHASE 3 STUDY
Mease, Philip
van der Heijde, Desiree
Landewe, Robert
Mpofu, Shephard
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Boettcher, Elke
Navarra, Sandra
Zhu, Xuan
Readie, Aimee
Abrams, Ken
Pricop, Luminita
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S10 - S10
[10] Subcutaneous Secukinumab Provides Sustained Inhibition of Radiographic Progression in Patients with Active Psoriatic Arthritis: 52-Week Results from a Phase 3 Study
Mease, Philip J.
van der Heijde, Desiree
Landewe, Robert B. M.
Mpofu, Shephard
Rahman, Proton
Tahir, Hasan
Singhal, Atul
Bottcher, Elke
Navarra, Sandra V.
Zhu, Xuan
Readie, Aimee
Pricop, Luminita
Abrams, Ken
ARTHRITIS & RHEUMATOLOGY, 2018, 70

← 1 2 3 4 5 →